This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Questions about our CME?
Questions about our CME?
Integrated Care Strategies to Address the Impact of Residual Symptoms on Functional Outcomes in MDD

Integrated Care Strategies to Address the Impact of Residual Symptoms on Functional Outcomes in MDD

Format

Webcast

Time to Complete

2 hours

Released

June 16, 2017

Expires

June 16, 2018
Add to Queue


Maximum Credits

2.00 / AAPA Category 1 CME Credits
2.00 / AANP Contact Hours (1.00 pharmacology credit)

Accredited Provider


This educational initiative is provided by CME Outfitters.

Commercial Supporter

This activity is supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc., and Lundbeck.

Program Description

Depression is one of the leading causes of disability worldwide. It affects individuals, families, businesses, and society and is common in patients seeking care in the primary care setting. Approximately 55% of patients will respond to treatment with the initial antidepressant.1 Yet, even in those patients who respond to treatment and achieve remission, residual symptoms can significantly inhibit functionality and increase the risk of relapse and recurrence.2

Despite these challenges, major depressive disorder (MDD) can be effectively managed, particularly when the clinician and patient mutually define what remission means to the patient and work together towards achieving sustained remission.

This CME Outfitters symposium on MDD features expert faculty offering new perspectives on treating this pervasive disorder, highlights residual symptoms as a challenge to clinicians, and ways to engage with patients to optimize management of all symptoms.
____________________________________________

References
1. Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D, implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
2. Zajecka JM. Residual symptoms and relapse: mood, cognitive symptoms, and sleep disturbances. J Clin Psychiatry. 2013;74(Suppl 2):9-13.

Intended Audience

Physicians assistants and nurse practitioners managing patients with major depression

Educational Objectives

At the end of this CE activity, participants should be able to:

  • Recognize the relationship between residual cognitive symptoms and functional impairment in patients with MDD
  • Assess all of the symptoms of MDD including cognitive and residual symptoms with a validated screening tool at each visit
  • Engage patients in shared decision-making to optimize their treatment options to manage all symptoms of MDD

Conflict Of Interest Disclosure Policy

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CME/CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CME/CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Faculty

Roger S. McIntyre, MD, FRCPC (Moderator)
Professor of Psychiatry and Pharmacology
University of Toronto
Executive Director
Brain and Cognition Discovery Foundation (BCDF)
Head, Mood Disorders Psychopharmacology Unit
University Health Network
Toronto, ON

Dr. McIntyre reports that he receives research grants from Allergan; AstraZeneca; Janssen Pharmaceuticals Inc.; Lundbeck; Otsuka; Pfizer Inc.; Purdue Pharma; and Shire. He serves on the advisory board for AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb Company; Forest Laboratories, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson; Lundbeck; Mitsubishi Tanabe Pharma Corporation; Moksha8 Pharmaceuticals Inc.; Otsuka; Pfizer Inc.; Purdue Pharma; Shire; Sunovion Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited. He receives speaker's fees from AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb Company; Forest Laboratories, Inc.; Janssen Pharmaceuticals, Inc.; Johnson & Johnson; Lundbeck; Mitsubishi Tanabe Pharma Corporation; Moksha8 Pharmaceuticals Inc.; Otsuka; Pfizer Inc.; Purdue Pharma; Shire; Sunovion Pharmaceuticals Inc.; and Takeda Pharmaceutical Company Limited.

Catherine Judd, MS, PA-C, CAQ-Psy, DFAAPA
Clinical Assistant Professor
Department of Physician Assistant Studies
UT Southwestern Medical Center School of Health Professions
Physician Assistant
Mental Health and Behavioral Medicine
Parkland Health and Hospital System
Dallas, TX

Ms. Judd reports that she serves on the speakers bureau for Sunovion Pharmaceuticals Inc. She is a consultant for Sunovion Pharmaceuticals Inc.

Gregory W. Mattingly, MD
Associate Clinical Professor
Washington University School of Medicine
St. Louis, MO
President
Midwest Research Group
St. Charles, MO

Dr. Mattingly reports that he receives research grants from Akili; Alcobra Pharma; Alkermes; Allergan; Boehringer Ingelheim; Forum Pharmaceuticals Inc.; Janssen Pharmaceuticals, Inc.; Medgenics, Inc.; NLS-1 Pharma AG; Reckitt Benckiser Group; Shire; Sunovion Pharmaceuticals Inc.; Supernus Pharmaceuticals, Inc.; and Takeda Pharmaceuticals U.S.A., Inc. He serves as a consultant for Alkermes, Allergan, Forum Pharmaceuticals Inc.; Lundbeck; Merck & Co., Inc.; Otsuka America Pharmaceutical, Inc.; Perdue Pharma L.P.; Rhodes Pharmaceuticals L.P.; Shire; Sunovion Pharmaceuticals, Inc.; Takeda Pharmaceuticals U.S.A.; and Vanda Pharmaceuticals.He receives speaker fee's from Allergan, Lundbeck, Merck & Co., Inc.; Otsuka America Pharmaceutical, Inc.; Shire; Sunovion Pharmaceuticals Inc.; Takeda Pharmaceuticals U.S.A.; and Vanda Pharmaceuticals.

Accredited Provider Disclosure

The CME Outfitters, LLC staff has nothing to disclose.

Planners' and Managers' Disclosures

Eva Hardy, MS, RN, ANP-B , (peer reviewer) has no disclosures to report.
Kashemi D. Rorie, PhD, (planning committee) has no disclosures to report.
Sharon Tordoff, CHCP, (planning committee) has no disclosures to report.
Jan Perez, CHCP, (planning committee) has no disclosures to report.

Credit

2.00

Type

AAPA Category I CME credit

Accreditation Statement

CME Outfitters, LLC, is approved by the Physician Assistant Review Panel.

Designation Statement

This program has been reviewed and is approved for a maximum of 2.00 hours of AAPA Category 1 CME credit by the Physician Assistant Review Panel. Approval is valid for one year from the issue date of 06/16/2017. Participants may submit the post-test at any time during that period.

This program was planned in accordance with AAPA's CME Standards for Enduring Material Programs and for Commercial Support of Enduring Material Programs.

Credit

2.00

Type

CE for Nurse Practitioners

Accreditation Statement

CME Outfitters, LLC, is approved by the American Association of Nurse Practitioners.

Designation Statement

This activity is approved 2.00 contact hour(s) of continuing education (which includes 1.00 hours of pharmacology) by the American Association of Nurse Practitioners.

Activity ID 17052683.

This activity was planned in accordance with AANP CE Standards and Policies.

Disclosure of Unlabeled Use

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.


Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions

There are no fees for participating in this CME/CE activity. To receive credit, participants must (1) read the learning objectives and disclosure statements, (2) study the educational activity, and (3) complete the post-test and activity evaluation form, including the certificate information section.

To obtain a certificate, participants must receive a score of 75% or better on the post-test. The post-test can be accessed at the end of the activity. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the accreditation of this activity, please contact info@cmeoutfitters.com.

If you have any other questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue